TriSalus Life Sciences to Host Second Quarter 2024 Financial Results Conference Call
TriSalus Life Sciences (Nasdaq: TLSI), an oncology company focusing on novel delivery technology integrated with immunotherapy for liver and pancreatic tumors, has announced a conference call and webcast scheduled for August 15, 2024, at 9:00 a.m. ET. The event will discuss financial results for the second quarter ended June 30, 2024, and provide a business update.
A press release detailing the Q2 results will be issued prior to the call. The webcast will be available on TriSalus' investor relations website, with a replay accessible for approximately 90 days after the event. Participants joining by phone must register using an online form to receive dial-in details and a personal pin.
TriSalus Life Sciences (Nasdaq: TLSI), un'azienda oncologica focalizzata su tecnologie di somministrazione innovative integrate con l'immunoterapia per tumori al fegato e al pancreas, ha annunciato una conferenza telefonica e un webcast programmati per 15 agosto 2024, alle 9:00 a.m. ET. L'evento tratterà i risultati finanziari per il secondo trimestre conclusosi il 30 giugno 2024 e fornirà un aggiornamento aziendale.
Un comunicato stampa dettagliato sui risultati del Q2 sarà pubblicato prima della chiamata. Il webcast sarà disponibile sul sito web delle relazioni con gli investitori di TriSalus, con una registrazione accessibile per circa 90 giorni dopo l'evento. I partecipanti che si uniscono tramite telefono devono registrarsi utilizzando un modulo online per ricevere i dettagli di accesso e un pin personale.
TriSalus Life Sciences (Nasdaq: TLSI), una empresa oncológica centrada en tecnologías de entrega innovadoras integradas con inmunoterapia para tumores de hígado y páncreas, ha anunciado una conferencia telefónica y un webcast programados para el 15 de agosto de 2024, a las 9:00 a.m. ET. El evento discutirá los resultados financieros del segundo trimestre que terminó el 30 de junio de 2024 y proporcionará una actualización empresarial.
Se emitirá un comunicado de prensa detallando los resultados del Q2 antes de la llamada. El webcast estará disponible en el sitio web de relaciones con inversores de TriSalus, con una repetición accesible durante aproximadamente 90 días después del evento. Los participantes que se unan por teléfono deben registrarse utilizando un formulario en línea para recibir los detalles de acceso y un pin personal.
TriSalus Life Sciences (Nasdaq: TLSI)는 간과 췌장 종양을 위한 면역 요법과 통합된 혁신적인 전달 기술에 중점을 둔 온콜로지 회사로, 2024년 8월 15일 오전 9시(ET)에 예정된 전화 회의 및 웹캐스트를 발표했습니다. 이 이벤트에서는 2024년 6월 30일로 종료된 2분기 재무 결과에 대해 논의하고 사업 업데이트를 제공합니다.
Q2 결과에 대한 자세한 보도 자료가 통화 전에 발행될 예정입니다. 웹캐스트는 TriSalus 투자자 관계 웹사이트에서 이용 가능하며, 이벤트 이후 약 90일간 재생할 수 있습니다. 전화로 참여하는 참가자는 온라인 양식을 사용하여 등록하여 접속 세부 정보와 개인 PIN을 받아야 합니다.
TriSalus Life Sciences (Nasdaq: TLSI), une société d'oncologie axée sur des technologies de livraison novatrices intégrées avec l'immunothérapie pour les tumeurs du foie et du pancréas, a annoncé une conférence téléphonique et un webcast prévus pour le 15 août 2024, à 9h00 ET. L'événement discutera des résultats financiers du deuxième trimestre se terminant le 30 juin 2024 et fournira une mise à jour de l'entreprise.
Un communiqué de presse détaillant les résultats du Q2 sera publié avant l'appel. Le webcast sera disponible sur le site des relations investisseurs de TriSalus, avec une rediffusion accessible pendant environ 90 jours après l'événement. Les participants rejoignant par téléphone doivent s'inscrire via un formulaire en ligne pour recevoir les détails de connexion et un code PIN personnel.
TriSalus Life Sciences (Nasdaq: TLSI), ein onkologisches Unternehmen, das sich auf neuartige Liefertechnologien in Kombination mit Immuntherapie für Leber- und Bauchspeicheldrüsen-Tumoren konzentriert, hat eine Telefonkonferenz und einen Webcast für den 15. August 2024, um 9:00 Uhr ET angekündigt. Die Veranstaltung wird die finanziellen Ergebnisse des zweiten Quartals, das am 30. Juni 2024 endete, erörtern und ein Unternehmensupdate geben.
Eine Pressemitteilung mit den Q2-Ergebnissen wird vor dem Anruf veröffentlicht. Der Webcast wird auf der Webseite für Investoren von TriSalus verfügbar sein, wobei eine Wiederholung für etwa 90 Tage nach der Veranstaltung zugänglich ist. Teilnehmer, die telefonisch teilnehmen möchten, müssen sich über ein Online-Formular registrieren, um die Zugangsdaten und eine persönliche PIN zu erhalten.
- None.
- None.
Call Scheduled for Thursday, August 15, 2024, at 9:00 a.m. ET
The event will be webcast live on the investor relations section of TriSalus’ website at https://investors.trisaluslifesci.com/news-events/events-presentations. Following the conclusion of the event, a webcast replay will be available on the website for approximately 90 days. Interested parties participating by phone will need to register using this online form. After registering for the webcast, dial-in details will be provided in an auto-generated e-mail containing a link to the conference phone number along with a personal pin.
About TriSalus Life Sciences
TriSalus Life Sciences® is an oncology focused medical technology business providing disruptive drug delivery technology with the goal of improving therapeutics delivery to liver and pancreatic tumors.
The Company’s platform includes devices that utilize a proprietary drug delivery technology and a clinical stage investigational immunotherapy. The Company’s two FDA-cleared devices use its proprietary Pressure-Enabled Drug Delivery™ (PEDD™) approach to deliver a range of therapeutics: the TriNav® Infusion System for hepatic arterial infusion of liver tumors and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. PEDD is a novel delivery approach designed to address the anatomic limitations of arterial infusion for the pancreas. The PEDD approach modulates pressure and flow in a manner that delivers more therapeutic to the tumor and is designed to reduce undesired delivery to normal tissue, bringing the potential to improve patient outcomes. Nelitolimod, the Company’s investigational immunotherapeutic candidate, is designed to improve patient outcomes by treating the immunosuppressive environment created by many tumors and which can make current immunotherapies ineffective in the liver and pancreas. Patient data generated during Pressure-Enabled Regional Immuno-Oncology™ (PERIO) clinical trials support the hypothesis that nelitolimod delivered via PEDD may have favorable immune effects within the liver and systemically. The target for nelitolimod, TLR9, is expressed across cancer types and the mechanical barriers addressed by PEDD are commonly present as well. Nelitolimod delivered by PEDD will be studied across several indications in an effort to address immune dysfunction and overcome drug delivery barriers in the liver and pancreas.
In partnership with leading cancer centers across the country – and by leveraging deep immuno-oncology expertise and inventive technology development – TriSalus is committed to advancing innovation that improves outcomes for patients. Learn more at trisaluslifesci.com and follow us on X (formerly Twitter) and LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240801658297/en/
For Media and Investor Inquiries:
Argot Partners
212.600.1902
TriSalus@argotpartners.com
Source: TriSalus Life Sciences
FAQ
When will TriSalus Life Sciences (TLSI) report its Q2 2024 financial results?
How can investors access TriSalus Life Sciences' (TLSI) Q2 2024 earnings call?
What period will TriSalus Life Sciences' (TLSI) Q2 2024 financial results cover?
Will there be a replay available for TriSalus Life Sciences' (TLSI) Q2 2024 earnings call?
